SCHEMBL6460814

SCHEMBL6460814

O=C(O)c1cccnc1Oc1ccc(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.52
PRMT6 Q96LA8 1/20 0.52
RAB9A P51151 1/20 0.51
TDP1 Q9NUW8 1/20 0.49
NAPRT Q6XQN6 1/20 0.49
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 2/20 0.48
PDE10A Q9Y233 2/20 0.47
MAPK8 P45983 2/20 0.45
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2336921 0.88 RAB9A (0.54) RAB9ATDP1NAPRTKMT2AALDH1A1
SCHEMBL27653419 0.85 TDP1 (0.67) CARM1PRMT6RAB9ATDP1KMT2A
SCHEMBL7367004 0.84 SLC22A12 (0.47) RAB9ATDP1NAPRTKMT2AALDH1A1
SCHEMBL2779361 0.84 KMT2A (0.65) RAB9ATDP1NAPRTKMT2AALDH1A1
SCHEMBL7313745 0.83 KMT2A (0.54) TDP1NAPRTKMT2AALDH1A1MAPK8
SCHEMBL7363608 0.82 KMT2A (0.53) RAB9ATDP1NAPRTKMT2AALDH1A1
SCHEMBL7369514 0.82 CARM1 (0.52) CARM1PRMT6RAB9ATDP1KMT2A
SCHEMBL2779334 0.81 RAB9A (0.76) RAB9ATDP1KMT2AALDH1A1PDE10A
SCHEMBL2332693 0.80 ALDH1A1 (0.61) RAB9ATDP1ALDH1A1MAPK8GAA
SCHEMBL5208228 0.80 PDE4A (0.53) CARM1PRMT6TDP1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed
US-6380218-B1 FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL PFIZER INC 2002-04-30 US disclosed
EP-0971894-A1 NICOTINAMIDE DERIVATIVES Pfizer Products Inc. (US) 2000-01-19 EP disclosed
WO-1998045268-A1 NICOTINAMIDE DERIVATIVES PFIZER PRODUCTS INC. (US) 1998-10-15 WO disclosed
EP-0053011-B1 NEW HERBICIDAL NICOTINAMIDE DERIVATIVES MAY & BAKER LIMITED (GB) 1985-04-03 EP disclosed
EP-0053011-A1 New herbicidal nicotinamide derivatives MAY & BAKER LIMITED (GB) 1982-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 CARM1 1622/4885PRMT6 575/4885RAB9A 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.